Ishika Govil
@ishikagovil.bsky.social
MIT ChemE PhD 👩🏻🔬 | Stark Lab
Reposted by Ishika Govil
Out now: We present antibody-lectin chimeras (AbLecs) as a molecular platform to target sugars, or glycans, for cancer immunotherapy.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social
Antibody-lectin chimeras for glyco-immune checkpoint blockade - Nature Biotechnology
Cancer immunotherapy benefits from antibody-lectin chimeras that block glyco-immune checkpoints.
www.nature.com
December 16, 2025 at 3:01 PM
Out now: We present antibody-lectin chimeras (AbLecs) as a molecular platform to target sugars, or glycans, for cancer immunotherapy.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social